# Sharp Edge Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sharp-edge-labs

- Industry: Biotechnology
- Headquarters: Pittsburgh, US
- Website: www.sharpedgelabs.com
- Total disclosed funding: $0.7M
- Latest round: Series C (Jun 30, 2017)
- Investors on record: 2

## About

Based in Pennsylvania, US, and founded in 2010, Sharp Edge Labs, Inc. operates as a biotechnology company that develops biosensors for patients with protein trafficking disorders. In August 2019, Sharp Edge Labs Inc. raised USD 3.547 million in venture funding. The firm as of June 2024, is led by its CEO/CSO Scott F. Sneddon, co-founder and CTO, Marcel Bruchez, and co-founder and chief architect, Alan Waggoner.

The company is dedicated to transforming the lives of patients with genetic diseases. Sharp develops small molecule drugs that restore the function of mutated proteins, to correct the fundamental imbalances caused by genetic mutations, turning diagnoses into hope for affected individuals. Sharp has focused on leveraging its unique suite of technologies—CoreX™, AlloChem™, and Disco™/Mine™. CoreX™ employs biology techniques to create sensitive assays that mimic disease states, facilitating the discovery of compounds that can correct mutational defects. AlloChem™ utilizes computational methods to design compound libraries enriched with drug-like correctors, which are then tested experimentally. Disco™/Mine™ integrates big data analytics and AI to enhance drug discovery, enabling the identification of effective treatments where traditional methods fall short.

## Funding rounds

- Series C, Jun 30, 2017 — Innovation Works
- Series B, Aug 19, 2014, $0.6M — Newlin Investment Company, Innovation Works
- Series B, Jul 24, 2014, $0.1M — Innovation Works

## Investors

- Innovation Works (https://capitalatlas.ai/funds/innovation-works) — Series B, Series C
- Newlin Investment Company — Series B